Background: US7 score is the ultrasound scoring system for rheumatic arthritis (RA) with the most clinical evidence so far. Several reports accessed its inter-, intra-observer agreement, its specificity, sensitivity and practical possibility compared to more complex scoring systems such as 72-joints scoring systems, which showed it is an convenient tool for clinical use. Objectives: Our goal is to employ US7 to investigate the ultrasonic changes during biological agents plus MTX Treatment in high disease activity refractory RA patients in Yellow people. Methods: All cases were diagnosed as RA fulfilling 2009 ACR/EULAR classification criteria and evaluated as high disease activity for DAS28>5.1 with MTX+HCQ+SASP or MTX+LEF invalid therapy for more than 3 months before baseline. Biological agents including TNF-a antagonist or IL-6 antagonist plus with MTX 10mg qw were then given and ultrasound was performed by 2 observers blinded to physicial examinations and blood tests at 0, 4, 12, 24, 48w. US examination referred to US7 scores by Backhaus et al. DAS28 were employed to assess disease activity. Results: 1) 26 subjects were enrolled in the program up to now. 22 were given TNF-a antagonists and 4 were given IL-6 antagonists. 17 finished 24 weeks follow-up. 1 withdrew for TB infection at 12 week and 1 withdrew for fungi pneumonia at 8 weeks. Mean age of 17 was 44.3±11.8 years old, female-male ratio was 15:2, and disease duration was 71 months. All were RF and ACPA postIve. :4w, 4w: 12w, 4w:24w, 12w:24w, sig = 0.083, 0.317, 0.102, 0.102). The above data showed the sum scores found biological agents improved thorough the whole course as Das28 did. Synovitis seemed to be eliminiated faster than tenosynovitis and the repair of bone erosion was the latest event compared to decreased synovitis and tenosynovitis. Conclusions: It is recommended US7 used in clinic for US7 scoring system could reflect more exquisitely than DAS28 in more refined aspects including the changes of tendon, joint, bone at different phrases during biological agent treatment for RA. However, more samples should be included in our study to illuminate above conclusion with sufficient evidence.
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Background: Co-factors and traditional cardiovascular disease (CVD) risk factors contribute to atherosclerosis in rheumatoid arthritis (RA). Several records since 1953 have reported an increase of up to 4 times the CVD risk and mortality in RA patients. Physicians who evaluate these patients forget to perform or record this assessments in medical records. Since 1948, the Framingham Heart Study became an ambitious project in health research, to identify the general causes of heart disease and stroke, they proposed a new risk estimator of general cardiovascular risk defined as CVD.This estimator was calibrated for Colombia and should be multiplied by a factor of 0.7 Objectives: To describe whether the request and registration of CV risk factors is performed. Also to estimate 10-year risk of CVD in RA patients and to compare the CVD risk among patients receiving or not biological therapy and those with positive and negative anti-cyclic citrullinated peptide (anti-CCP) Methods: We conducted an observational descriptive study of patients who attended a specialized rheumatology clinic in Bogotá, Colombia from 2010 to 2015. Patients with RA were enrolled who had completed at least 5 year of follow-up. The information required to estimate CVD risk was obtained from medical records. Other variables included were biological therapy and test result of anti-CCP. For the calculation of CVD risk, the Framingham estimator was used and adjusted for the Colombian population. Additionally, patients who had 2 or more of these criteria: More than 10 years of evolution of RA, positive rheumatoid factor and/or extra-articular compromise, the risk was adjusted by multiplying by 1.5. Nonparametric statistics (Mann-Whitney U test) was used. Results: We identified 273 eligible patients with RA with mean age 61, 66% women. Only 117 (42.8%) had recorded in their charts all variables to calculate CVD risk. We found that 32% had high blood pressure, 7% type II DM, 11% Obesity and 13% smoking. For the population evaluated, 10-year CVD risk median was 12.42% and for Colombia was 8.69%, adjusting this risk according to the disease in Colombia, increased to 13.03%. When we compare the 10-year CVD risk in anti-CCP positive patients (median: 11.15) and anti-CCP negative (median: 8.22) we did not find difference (p: 0.614). However, we found differences in the 10-year CVD risk median 9.04 vs. 23.25, 10-year CVD risk adjusted to Colombia median 6.32 vs. 16.31 and 10-year CVD risk adjusted to Colombia and RA median 6.81 vs. 13.39 between patients using biological therapy versus patients without receiving respectively (p: <0.001) Conclusions: Only 42.8% of the sample had all CV risk factors requested and registered in the clinical record, so should promote improvement in the health team to increase this. The average 10-year CVD risk in all people with RA was 12.42%, and in patients who met the criteria to be multiplied by the factor 1.5 increased to 13.03%, which means that these patients should be reported this and applied risk prevention guidelines regarding obesity and cholesterol levels. Despite population receiving biologics are younger, they had lower CV risk. We need more research to confirm this results Objectives: The aim of the study was to evaluate parameters of (AS) and their associations with inflammatory activity in patients with RA. Methods: 62 patients with RA (EULAR 2010) without known CVD were examined (73% females,age 58,5±15,4 (M±SD) years, 13% smokers, 61% with AH, 34% with dyslipidemia). Median duration of RA was 8 years . Seropositive RA was diagnosed in 69% of patients. Median hsCRP was 12,1 mg/dl (IQR 2,2;23,4 mg/dl), median rheumatoid factor (RF) was 32,5 IU/ml (IQR 8,3;173 IU/ml). Mean DAS-28 (ESR) was 4,7±1,2. All patients received disease-modifying antirheumatic drugs, 22 (38%) -biological treatment. Parameters of AS were assessed by applanation tonometry (SphygmoCor, AtCor). Cardio-ankle vascular index (CAVI), ankle-brachial index (ABI) and vascular age were measured by VaSera 1500. Carotid intima-media thickness (CIMT) was evaluated by ultrasound. Pulse wave velocity>10,0 m/s and CAVI>9,0 were considered as AS increase. ABI<0,9 and CIMT>0,9 were considered as markers of subclinical atherosclerosis. p<0.05 was significant. Results: Mean PWV was 9,3±3,2 m/s. PWV>10m/s was observed in 32,3% patients, CAVI>9,0 -in 25,8%, ABI<0,9 -in 6,5% and CIMT>0,9 -in 21%. Patients with PWV>10m/s were older (69,8±8,5 vs 53,2±15,1 years), had higher BMI (29,3±6,5 vs 24,7±4,8 kg/m 2 ), longer duration of AH (median 11, 5 [IQR 5, 5 ;17] vs 0 [IQR 0;5] years), higher BP levels (144±20/85±9 vs 123±14/77±10 mmHg), lower level of GFR (64±17 vs 89±19 ml/min/1,73m
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2 ), higher levels of LDL-C (3,7±0,9 vs 3,2±1,0 mmol/l), plasma glucose (5,6±0,9 vs 4,8±0,7 mmol/l), hs-CRP (median 22 [IQR 13, 3 ;60] vs 6,7 [IQR 1,6;17,2] mg/dl), higher CAVI (9,5±1,1 vs 7,6±1,4), vascular age (71±8,4 vs 53,4±17,5 years) and CIMT (1,01±0,3 vs 0,7±0,2 mm), p<0,05 for trend. Spearmen analysis revealed significant positive correlations between PWV and age (r=0,7), BMI (r=0,4), duration of AH (r=0,6), SBP (r=0,6), DBP (r=0,4), plasma glucose (r=0,3), hs-CRP (r=0,3), vascular age (r=0,6), CIMT (r=0,7), CAVI (r=0,6) and negative correlations with eGFR (r=-0,6). hsCRP correlated with PWV, aortic pulse pressure (r=0,3), CAVI (r=0,5), vascular age (r=0,5) and ABI (r=-0,5). Multiple regression analysis confirmed that AH duration (β=0,2, p=0.03), SBP (β=0,6, p<0.0001), GFR (β=-0,3, p=0,005) and hs-CRP-level (β=0,3, p=0.000009) were independent predictors of AS increase. Conclusions: High prevalence of AS increase is observed in patients with RA without known CVD. Elevation of hsCRP as well as other traditional risk factors is an independent predictor of PWV increase in patients with RA.
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